Navigation Links
Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody
Date:3/22/2012

t 8:25 AM.

About PCSK9
PCSK9 is known to be a determinant of circulating LDL levels, as it binds to LDL receptors resulting in their degradation so that fewer are available on liver cells to remove excess LDL-cholesterol from the blood.  Moreover, traditional LDL-lowering therapies such as statins actually stimulate the production of PCSK9, which may limit their ability to lower LDL-cholesterol.  Blocking the PCSK9 pathway is therefore a potentially novel mechanism for lowering LDL-cholesterol.

About REGN727
REGN727/SAR236553 is a fully-human monoclonal antibody directed against PCSK9, administered via subcutaneous injection.  By inhibiting PCSK9, a determinant of circulating LDL-cholesterol levels in the blood, REGN727 increases the number of free LDL receptors which can bind to circulating LDL and clear it from the bloodstream.  REGN727 was created using Regeneron's pioneering VelocImmune® technology and is being developed by Regeneron in collaboration with Sanofi.

About Regeneron Pharmaceuticals
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, one for the treatment of neovascular (wet) age-related macular degeneration and another for the treatment of a rare inflammatory condition.  Additionally, Regeneron has three regulatory applications pending before the U.S. Food and Drug Administration (FDA) and 10 drug candidates in clinical development.  More information and recent news releases are available on the Regeneron web site at www.regeneron.com

Regeneron Forward-Looking Statement
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performan
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  Surgical Theater, LLC announced today the ... Advisory Board. New members include Ori J. ... Development and New Technologies for Given Imaging Ltd., ... Vice President and General Manager of Philips Healthcare,s ... simulation technology to brain surgery and has developed ...
(Date:7/28/2014)... July 28, 2014  Air Products (NYSE: ... medical oxygen is vital to any healthcare facility. This ... not only improve the efficiency of its oxygen supply ... highlight these systems—including systems for emergency oxygen supply ... August 4-5 at the 51 st ASHE ...
(Date:7/28/2014)... -- UBM Medica US announces that Diagnostic Imaging ... professionals, explored the complex situation regarding measuring the ... The shift from fee-for-service has left radiology at a ... determined in the new payment model . ... who recognized the complexity of the radiologist,s value: ...
Breaking Medicine Technology:Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 2Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 3Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 4Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 5Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3Diagnostic Imaging Delves into Measuring the Radiologist's Value 2
... Valeant Pharmaceuticals International, Inc. (the "Company" or "Valeant") ... Intention to make a normal course issuer bid with ... TSX has accepted the Notice of Intention. Under the ... for cancellation, commencing August 25, 2011, 1,000,000 of its ...
... a leading provider of healthcare IT and medical billing solutions, ... 2011 Inc. 5000 list, a compendium of the most entrepreneurial ... the second year in a row that ITelagen qualified for ... position #2093, with an extraordinary four-year growth rate of 120.22%. ...
Cached Medicine Technology:Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid 2Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid 3ITelagen Named to Prestigious 2011 Inc. 5000 List of Fastest-Growing Companies 2
(Date:7/28/2014)... --,The more chronic medical conditions people have at retirement ... new study claims. Since nearly four in ... Johns Hopkins Bloomberg School of Public Health in Baltimore ... life expectancy are slowing in the United States. ... disease and heart failure is now the norm and ...
(Date:7/28/2014)... 2014 (HealthDay News) -- Endurance runners are far more ... heart condition, according to a new study. ... events in warm climates are actually 10 times more ... the less common sudden death of a young and ... as an irregular heartbeat, often gets a lot more ...
(Date:7/28/2014)... Most cells do not divide unless there is enough ... cells and other cell types circumvent this rule. Researchers ... mechanism that overrides the cells, warning signals, enabling cancers ... supply. In the process, the researchers found that lysosomes ... cell division decisions. They also uncovered new evidence that ...
(Date:7/28/2014)... Washington, NY (PRWEB) July 28, 2014 Parker ... many years fighting to ensure that the heroes of 9/11 ... Fund (VCF) has announced an important deadline. According to a ... were diagnosed with a covered cancer on or before October ... October 12, 2014. First responders and others who were allegedly ...
(Date:7/28/2014)... July 28, 2014 The Brooke ... has donated more than 200,000 books to children and ... the launch of Brooke’s Cooks, a new initiative designed ... healthy living among at-risk children and their families in ... a series of nutrition information workshops, cooking demonstrations and ...
Breaking Medicine News(10 mins):Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2Health News:Cell's recycling center implicated in division decisions 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 4
... Rare Diseases, BETHESDA, Md., April 24 ... of Representatives for passing,legislation to reauthorize the Small ... testimony from Robert J. Beall, Ph.D., president and ... requiring that,special attention be given to research for ...
... The following are,excerpts from an article in The ... Republican National Committee:, Congressional Democrats are backing away ... saying that even if,their party controls the White House ... some senators, the promises made by Sens. Barack Obama ...
... (Nasdaq: ONXX ) today announced that it ... Conference on Thursday,May 1, at 8:00 a.m. Eastern ... of the presentation on our website at:, ... listeners log on 15 minutes early in order ...
... how brain cell communication may be altered in schizophrenia ... at the Medical College of Georgia, a 2008 Distinguished ... Alliance Eminent Scholar in Neuroscience and professor in the ... of 11 scientists to receive the award, which includes ...
... Perrigo Company,(Nasdaq: PRGO ; TASE) today announced that ... Administration (FDA) to market over-the-counter (OTC),Nicotine Polacrilex Gum USP, ... The FDA has determined the product to be ... mg (base) and 4 mg,(base), which is an aid ...
... April 24 Karen Ignagni,President and CEO ... issued,the following statement commending the Senate on ... Senate:, (Logo: http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ), ... the basis of their genetic,makeup. We applaud ...
Cached Medicine News:Health News:Cystic Fibrosis Foundation Lauds Congress for Passage of Small Business Innovation Research Program 2Health News:RNC: Dems Hedge on Healthcare 2Health News:Dr. Mei honored by mental health research charity for schizophrenia studies 2Health News:Dr. Mei honored by mental health research charity for schizophrenia studies 3Health News:Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum 2
... Conduit TCP is a synthetic porous ceramic ... similar to the mineral phase that comprises 70% ... that provides a scaffold that allows the attachment ... development of vascular networks within granules as well ...
Schuknecht-Weitlaner retractor, sharp, angled arms....
Weitlaner Beckmann retractor, sharp prongs, SS....
Scoville sharp curette, 10, straight, scoop size 4 x 10 mm....
Medicine Products: